Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac

Heberprovac is a GnRH based vaccine candidate containing 2.4 mg of the GnRHm1-TT peptide as the main active principle; 245 μg of the very small size proteoliposomes adjuvant (VSSP); and 350 μL of Montanide ISA 51 VG oil adjuvant. The aim of this study was to assess the safety and tolerance of the He...

Descripción completa

Detalles Bibliográficos
Autores principales: Junco, Jesús A., Rodríguez, Ranfis, Fuentes, Franklin, Baladrón, Idania, Castro, Maria D., Calzada, Lesvia, Valenzuela, Carmen, Bover, Eddy, Pimentel, Eulogio, Basulto, Roberto, Arteaga, Niurka, Cid-Arregui, Angel, Sariol, Francisco, González, Lourdes, Porres-Fong, Liliana, Medina, María, Rodríguez, Ayni, Garay, A. Hilda, Reyes, Osvaldo, López, Matilde, de Quesada, Lourdes, Alvarez, Allelin, Martínez, Carolina, Marrero, Marleny, Molero, Guillermo, Guerra, Alfredo, Rosales, Pedro, Capote, Carlos, Acosta, Sahily, Vela, Idania, Arzuaga, Lina, Campal, Ana, Ruiz, Erlán, Rubio, Elier, Cedeño, Pável, Sánchez, María Carmen, Cardoso, Pedro, Morán, Rolando, Fernández, Yairis, Campos, Magalys, Touduri, Henio, Bacardi, Dania, Feria, Indalecio, Ramirez, Amilcar, Cosme, Karelia, Saura, Pedro López, Quintana, Maricel, Muzio, Verena, Bringas, Ricardo, Ayala, Marta, Mendoza, Mario, Fernández, Luis E., Carr, Adriana, Herrera, Luis, Guillén, Gerardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397853/
https://www.ncbi.nlm.nih.gov/pubmed/30859088
http://dx.doi.org/10.3389/fonc.2019.00049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397853/
https://www.ncbi.nlm.nih.gov/pubmed/30859088
http://dx.doi.org/10.3389/fonc.2019.00049

Ejemplares similares